|
Market Closed -
Nasdaq
02:30:00 17/01/2026 am IST
|
5-day change
|
1st Jan Change
|
|
43.96 USD
|
-3.26%
|
 |
-0.18%
|
+0.30%
|
|
13/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.
|
CI
| |
13/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on February 20, 2025.
|
CI
| |
12/01 |
Independence, Under Review
|  | |
12/01 |
Exelixis Provides Fiscal 2026 Revenue Guidance
|
MT
| |
12/01 |
Exelixis says fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion
|
RE
| |
12/01 |
Exelixis, Inc. Announces Preliminary Financial Results for the Year 2025 and Provides Financial Guidance for the Year 2026
|
CI
| |
07/01 |
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial
|
MT
| |
07/01 |
Exelixis, Inc. and Natera Announce to Collaborate on STELLAR-316, Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
|
CI
| |
31/12 |
Exelixis, Inc.'s Equity Buyback announced on February 20, 2025, has closed with 12,271,791 shares, representing 4.5% for $500 million.
|
CI
| |
05/11 |
Exelixis Inc authorizes $750 million stock repurchase by 2026 - SEC filing
|
RE
| |
05/11 |
Exelixis Q3 Non-GAAP Earnings, Revenue Increase
|
MT
| |
05/11 |
Exelixis Q3 revenue beats analyst expectations
|
RE
| |
05/11 |
Earnings Flash (EXEL) Exelixis, Inc. Posts Q3 Adjusted EPS $0.78 per Share, vs. FactSet Est of $0.69
|
MT
| |
05/11 |
Earnings Flash (EXEL) Exelixis, Inc. Reports Q3 Revenue $597.8M, vs. FactSet Est of $590.2M
|
MT
| |
05/11 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on February 20, 2025.
|
CI
| |
05/11 |
Exelixis, Inc. announces an Equity Buyback for $750 million worth of its shares.
|
CI
| |
05/11 |
Exelixis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
| |
05/11 |
Exelixis, Inc. Updates Earnings Guidance for Fiscal Year 2025
|
CI
| |
04/11 |
Exelixis, Inc. authorizes a Buyback Plan.
|
CI
| |
20/25/20 |
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Earnings Take Center Stage
|
MT
| |
20/25/20 |
Exelixis, Inc. Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025
|
CI
| |
18/25/18 |
Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
|
CI
| |
16/25/16 |
Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
|
CI
| |
16/25/16 |
Adagene Expands Agreement With Exelixis For SAFEbody Technology Platform; Adagene Shares Up Pre-Bell
|
MT
| |
29/25/29 |
All that for this!
| |
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
